Claims for Patent: 9,862,767

Summary for Patent: 9,862,767

Title:	Therapeutic methods using anti-CD200 antibodies
Abstract:	The present disclosure relates to anti-CD200 antibodies and to use of the antibodies in methods for treating autoimmune disorders and cancer. Also featured are biomarkers for use in selecting or prescribing a treatment modality for a patient with an autoimmune disorder and/or cancer. In addition, the disclosure features methods of treatment using an anti-CD200 antibody in combination with one or more additional therapeutic agents such as an anti-CD20 therapeutic agent.
Inventor(s):	Rother; Russell P. (Oklahoma City, OK), Yan; Yan (Cheshire, CT)
Assignee:	Alexion Pharmaceuticals, Inc. (New Haven, CT)
Application Number:	14/739,862
Patent Claims:	1. A method for treating a human afflicted with a cancer, the method comprising administering to the human an anti-CD200 antibody, or a CD200-binding fragment thereof, in an amount that is sufficient to treat the cancer, wherein the cancer is resistant, or is suspected of being resistant, to therapy with an anti-CD20 antibody, wherein the anti-CD200 antibody, or CD200-binding fragment thereof, contains one of the following paired set of CDRs: (i) a HCDR1 comprising the amino acid sequence: GFNIKDYYMH (SEQ ID NO:10); a HCDR2 comprising the amino acid sequence: WIDPENGDTKYAPKFQG (SEQ ID NO:11); a HCDR3 comprising the amino acid sequence: KNYYVSNYNFFDV (SEQ ID NO:12); a LCDR1 comprising the amino acid sequence: SASSSVRYMY (SEQ ID NO:13); a LCDR2 comprising the amino acid sequence: DTSKLAS (SEQ ID NO:14); and a LCDR3 comprising the amino acid sequence: FQGSGYPLT (SEQ ID NO:15); (ii) a HCDR1 comprising the amino acid sequence: GFNIKDYYIH (SEQ ID NO:16); a HCDR2 comprising the amino acid sequence: WIDPEIGATKYVPKFQG (SEQ ID NO:17); a HCDR3 comprising the amino acid sequence: LYGNYDRYYAMDY (SEQ ID NO:18); a LCDR1 comprising the amino acid sequence: KASQNVRTAVA (SEQ ID NO:19); a LCDR2 comprising the amino acid sequence: LASNRHT (SEQ ID NO:20); and a LCDR3 comprising the amino acid sequence: LQHWNYPLT (SEQ ID NO:21); (iii) a HCDR1 comprising the amino acid sequence: GYSFTDYIIL (SEQ ID NO:22); a HCDR2 comprising the amino acid sequence: HIDPYYGSSNYNLKFKG (SEQ ID NO:23); a HCDR3 comprising the amino acid sequence: SKRDYFDY (SEQ ID NO:24); a LCDR1 comprising the amino acid sequence: KASQDINSYLS (SEQ ID NO:25); a LCDR2 comprising the amino acid sequence: RANRLVD (SEQ ID NO:26); and a LCDR3 comprising the amino acid sequence: LQYDEFPYT (SEQ ID NO:27); (iv) a HCDR1 comprising the amino acid sequence: GYTFTEYTMH (SEQ ID NO:28); a HCDR2 comprising the amino acid sequence: GVNPNNGGALYNQKFKG (SEQ ID NO:29); a HCDR3 comprising the amino acid sequence: RSNYRYDDAMDY (SEQ ID NO:30); a LCDR1 comprising the amino acid sequence: KSSQSLLDIDEKTYLN (SEQ ID NO:31); a LCDR2 comprising the amino acid sequence: LVSKLDS (SEQ ID NO:32); and a LCDR3 comprising the amino acid sequence: WQGTHFPQT (SEQ ID NO:33); or (v) a HCDR1 comprising the amino acid sequence: AFNIKDHYMH (SEQ ID NO:34); a HCDR2 comprising the amino acid sequence: WIDPESGDTEYAPKFQG (SEQ ID NO:35); a HCDR3 comprising the amino acid sequence: FNGYQALDQ (SEQ ID NO:36); a LCDR1 comprising the amino acid sequence: TASSSVSSSYLH (SEQ ID NO:37); a LCDR2 comprising the amino acid sequence: STSNLAS (SEQ ID NO:38); and a LCDR3 comprising the amino acid sequence: RQYHRSPPIFT (SEQ ID NO:39). 2. The method of claim 1, wherein the cancer comprises cancer cells that express CD5. 3. The method of claim 1, wherein the cancer is a liquid tumor. 4. The method of claim 3, wherein the liquid tumor is a chronic lymphocytic leukemia or multiple myeloma. 5. The method of claim 4, wherein the chronic lymphocytic leukemia is a B cell chronic lymphocytic leukemia. 6. The method of claim 1, further comprising administering to the human an anti-CD20 therapeutic agent. 7. The method of claim 6, wherein the anti-CD20 therapeutic agent is an anti-CD20 antibody or a CD20-binding fragment thereof. 8. The method of claim 7, wherein the anti-CD20 antibody is rituximab, ofatumumab, TRU-015, veltuzumab, ocrelizumab, or AME-133v. 9. The method of claim 7, wherein the anti-CD20 antibody, or CD20-binding fragment thereof, is conjugated to a toxin. 10. The method of claim 1, wherein the anti-CD200 antibody, or CD200-binding fragment thereof, is a bispecific antibody comprising a first antigen combining site that binds to CD200 and a second antigen combining site that binds to CD20. 11. The method of claim 1, wherein the anti-CD200 antibody, or CD200-binding fragment thereof, inhibits the interaction between CD200 and CD200R. 12. The method of claim 1, wherein the anti-CD200 antibody, or CD200-binding fragment thereof, is murine, chimeric, humanized, or fully human. 13. The method of claim 1, wherein the CD200-binding fragment is selected from the group consisting of a Fab fragment, a F(ab').sub.2 fragment, a Fab' fragment, an scFv fragment, a minibody, a diabody, or a triabody.

Details for Patent 9,862,767

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2030-02-11
Novartis Pharmaceuticals Corporation	ARZERRA	ofatumumab	Injection	125326	10/26/2009		2030-02-11
Novartis Pharmaceuticals Corporation	ARZERRA	ofatumumab	Injection	125326	04/01/2011		2030-02-11
Novartis Pharmaceuticals Corporation	KESIMPTA	ofatumumab	Injection	125326	08/20/2020		2030-02-11
Genentech, Inc.	OCREVUS	ocrelizumab	Injection	761053	03/28/2017		2030-02-11
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064	06/22/2017		2030-02-11